Biolexis Therapeutics

Biolexis Therapeutics is a privately held clinical-stage biopharmaceutical company dedicated to developing small molecule drugs for cancer, immune-mediated, neurodegenerative, autoimmune, metabolic, and inflammatory diseases. Through its proprietary MolecuLern AI drug discovery process, Biolexis rapidly discovers and develops new clinical candidates with unprecedented speed and accuracy.